Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program Participants, 2 January to 18 March 2020
| Autor: | Sheri D. Schully, James Michael Cherry, Hoda Anton-Culver, Keri N. Althoff, Adrienne S. Roman, Isaac P. Thomsen, Carolyn Williams, Mine S. Cicek, Joshua C. Denny, Kelly A. Gebo, Ligia A. Pinto, David Goldstein, Bradley A. Malin, David Jeffrey Schlueter, Lucila Ohno-Machado, Elizabeth W. Karlson, Aymone Kouame, Fiona Havers, Andrea H. Ramirez, Douglas R. Lowy, Stephen N. Thibodeau, Norman E. Sharpless |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
2019-20 coronavirus outbreak medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Epidemic Enzyme-Linked Immunosorbent Assay Antibodies Viral Microbiology Medical and Health Sciences Sensitivity and Specificity Antibodies Vaccine Related Clinical Research Biodefense Correspondence Major Article medicine Humans Viral Igg elisa Lung Immunoglobulin G antibodies Gynecology Population Health business.industry SARS-CoV-2 Prevention COVID-19 Pneumonia Biological Sciences United States Emerging Infectious Diseases All of Us Research Program Infectious Diseases AcademicSubjects/MED00290 Severe acute respiratory syndrome-related coronavirus Immunoglobulin G business |
| Zdroj: | Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol 74, iss 4 |
| ISSN: | 1537-6591 |
| Popis: | Background With limited severe acute respiratory syndrome coronavirus (SARS-CoV-2) testing capacity in the United States at the start of the epidemic (January–March 2020), testing was focused on symptomatic patients with a travel history throughout February, obscuring the picture of SARS-CoV-2 seeding and community transmission. We sought to identify individuals with SARS-CoV-2 antibodies in the early weeks of the US epidemic. Methods All of Us study participants in all 50 US states provided blood specimens during study visits from 2 January to 18 March 2020. Participants were considered seropositive if they tested positive for SARS-CoV-2 immunoglobulin G (IgG) antibodies with the Abbott Architect SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) and the EUROIMMUN SARS-CoV-2 ELISA in a sequential testing algorithm. The sensitivity and specificity of these ELISAs and the net sensitivity and specificity of the sequential testing algorithm were estimated, along with 95% confidence intervals (CIs). Results The estimated sensitivities of the Abbott and EUROIMMUN assays were 100% (107 of 107 [95% CI: 96.6%–100%]) and 90.7% (97 of 107 [83.5%–95.4%]), respectively, and the estimated specificities were 99.5% (995 of 1000 [98.8%–99.8%]) and 99.7% (997 of 1000 [99.1%–99.9%]), respectively. The net sensitivity and specificity of our sequential testing algorithm were 90.7% (97 of 107 [95% CI: 83.5%–95.4%]) and 100.0% (1000 of 1000 [99.6%–100%]), respectively. Of the 24 079 study participants with blood specimens from 2 January to 18 March 2020, 9 were seropositive, 7 before the first confirmed case in the states of Illinois, Massachusetts, Wisconsin, Pennsylvania, and Mississippi. Conclusions Our findings identified SARS-CoV-2 infections weeks before the first recognized cases in 5 US states. Seven individuals had detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G before the first confirmed cases in Illinois, Massachusetts, Wisconsin, Pennsylvania, and Mississippi, suggesting that SARS-CoV-2 infections occurred weeks before recognized cases in at least 5 US states. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|